JP2009525323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525323A5 JP2009525323A5 JP2008553193A JP2008553193A JP2009525323A5 JP 2009525323 A5 JP2009525323 A5 JP 2009525323A5 JP 2008553193 A JP2008553193 A JP 2008553193A JP 2008553193 A JP2008553193 A JP 2008553193A JP 2009525323 A5 JP2009525323 A5 JP 2009525323A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- sequence
- stathmin
- tlr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 102000008230 Toll-like receptor 3 Human genes 0.000 claims 15
- 108010060885 Toll-like receptor 3 Proteins 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000002243 precursor Substances 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 101000697502 Homo sapiens Stathmin-3 Proteins 0.000 claims 4
- 102100028052 Stathmin-3 Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000005465 Stathmin Human genes 0.000 claims 3
- 108050003387 Stathmin Proteins 0.000 claims 3
- 230000003412 degenerative effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000025535 REM sleep behavior disease Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 239000004135 Bone phosphate Substances 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 101000697510 Homo sapiens Stathmin-2 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 102100028051 Stathmin-2 Human genes 0.000 claims 1
- 102000019355 Synuclein Human genes 0.000 claims 1
- 108050006783 Synuclein Proteins 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 206010044541 Traumatic shock Diseases 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06075265A EP1815863A1 (en) | 2006-02-03 | 2006-02-03 | Use of TLR3 agonists for the treatment of neurodegenerative disorders |
| PCT/NL2007/050045 WO2007089151A1 (en) | 2006-02-03 | 2007-02-02 | Use of tlr3 agonists for the treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009525323A JP2009525323A (ja) | 2009-07-09 |
| JP2009525323A5 true JP2009525323A5 (enExample) | 2010-03-25 |
Family
ID=36087734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553193A Pending JP2009525323A (ja) | 2006-02-03 | 2007-02-02 | 神経変性疾患の処置の為にｔｌｒ３アゴニストを使用する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090253622A1 (enExample) |
| EP (2) | EP1815863A1 (enExample) |
| JP (1) | JP2009525323A (enExample) |
| AU (1) | AU2007210379A1 (enExample) |
| WO (1) | WO2007089151A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100130425A1 (en) * | 2005-09-09 | 2010-05-27 | Oregon Health & Science University | Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia |
| WO2008083351A2 (en) | 2006-12-29 | 2008-07-10 | Genifuel Corporation | Controlled growth environments for algae cultivation |
| GB201022049D0 (en) * | 2010-12-29 | 2011-02-02 | Imp Innovations Ltd | Methods |
| EP2687224A1 (en) * | 2012-07-19 | 2014-01-22 | Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH | Medicament for wound treatment |
| WO2015108595A1 (en) | 2014-01-15 | 2015-07-23 | Nikolai Khodarev | Anti-tumor therapy |
| US10105305B2 (en) * | 2014-02-19 | 2018-10-23 | The Johns Hopkins University | Compositions and methods for promoting skin regeneration and hair growth |
| EP3298131B1 (en) | 2015-05-20 | 2023-04-26 | The Regents of The University of California | Method for generating human dendritic cells for immunotherapy |
| CA3003145C (en) | 2015-10-30 | 2025-11-18 | The Regents Of The University Of California | METHODS FOR GENERATION OF T LYMPHOCYTES FROM STEM CELLS AND IMMUNOTHERAPY METHODS USING SAID T LYMPHOCYTES |
| EP3318270A1 (en) * | 2016-11-08 | 2018-05-09 | RMB-Research GmbH | Stathmin composition and method for treating wounds |
| EP3538668B8 (en) | 2016-11-10 | 2025-04-23 | Talis Biomedical Corporation | Polynucleotides for the amplification and detection of chlamydia trachomatis |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112223A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| US10450616B1 (en) | 2018-05-09 | 2019-10-22 | Talis Biomedical Corporation | Polynucleotides for the amplification and detection of Chlamydia trachomatis |
| US12496327B2 (en) | 2019-01-14 | 2025-12-16 | President And Fellows Of Harvard College | Methods and compositions for restoring STMN2 levels |
| US11969402B2 (en) | 2019-05-16 | 2024-04-30 | The Johns Hopkins University | Compositions and methods for skin rejuvenation |
| US20220333105A1 (en) * | 2019-06-03 | 2022-10-20 | Quralis Corporation | Oligonucleotides and methods of use for treating neurological diseases |
| WO2021076964A1 (en) * | 2019-10-17 | 2021-04-22 | Icahn School Of Medicine At Mount Sinai | Stathmin 2 (stmn2) as a therapeutic target for parkinson's disease |
| US11891662B2 (en) * | 2019-12-02 | 2024-02-06 | Talis Biomedical Corporation | Polynucleotides for amplification and detection of human beta actin |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| US11047007B1 (en) | 2020-03-23 | 2021-06-29 | Talis Biomedical Corporation | Polynucleotides for amplification and detection of SARS-CoV-2 |
| WO2022003598A1 (en) | 2020-07-02 | 2022-01-06 | Viiv Healthcare Company | Method of achieving hiv viral remission using long-acting antiretroviral agents |
| CN117320722A (zh) | 2021-04-28 | 2023-12-29 | 埃尼奥制药公司 | 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044935A1 (en) * | 1997-06-11 | 2003-03-06 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
| EP1242443A4 (en) * | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| AU2002220131A1 (en) * | 2000-12-01 | 2002-06-11 | Board Of Trustees Of The University Of Arkansas | Compositions, methods, apparatus and products comprising a stathmin/oncoprotein 18 sequence for detecting and treating cancer |
| EP1288226A1 (en) * | 2001-09-03 | 2003-03-05 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system |
| AU2003302386B2 (en) * | 2002-11-26 | 2010-04-01 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004078925A2 (en) * | 2003-02-28 | 2004-09-16 | Irm Llc | Methods and compositions for treating and preventing neurodegenerative diseases |
| US7396654B2 (en) * | 2004-04-15 | 2008-07-08 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for traumatic brain injury |
-
2006
- 2006-02-03 EP EP06075265A patent/EP1815863A1/en not_active Withdrawn
-
2007
- 2007-02-02 JP JP2008553193A patent/JP2009525323A/ja active Pending
- 2007-02-02 EP EP07715865A patent/EP1991251A1/en not_active Ceased
- 2007-02-02 US US12/162,916 patent/US20090253622A1/en not_active Abandoned
- 2007-02-02 AU AU2007210379A patent/AU2007210379A1/en not_active Abandoned
- 2007-02-02 WO PCT/NL2007/050045 patent/WO2007089151A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525323A5 (enExample) | ||
| MX2024000208A (es) | Restos de administracion terapeutica novedosos y usos de estos. | |
| MXPA05011524A (es) | Acidos carboxilicos sustituidos. | |
| MXPA05010937A (es) | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. | |
| AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| MX2009007136A (es) | Metodos para suministrar moleculas y objetivos de enlace especificos de enfermedades. | |
| MX336966B (es) | Novedosos derivados y su uso en el tratamiento de transtornos neurologicos. | |
| EA200700212A1 (ru) | Многовалентные vla-4 антагонисты, содержащие полимерные фрагменты | |
| MY162502A (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| EP4552692A3 (en) | Cns gene delivery using peripheral administration of aav vectors | |
| TW200630327A (en) | Substituted phenylalkanoic acids | |
| EA201200002A1 (ru) | Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний | |
| MX2018006955A (es) | Terapia genica para trastornos neurodegenerativos. | |
| MXPA05011539A (es) | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. | |
| MXPA05010293A (es) | 4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas. | |
| JP2012508254A (ja) | α７選択的リガンドを用いる治療 | |
| JP2014510101A5 (enExample) | ||
| UA101393C2 (ru) | КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ | |
| EA200800975A1 (ru) | ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ | |
| WO2011056477A3 (en) | Methods for treating inflammation and oxidative stress related diseases | |
| TW200630354A (en) | Substituted amino carboxylic acids | |
| FR2918282B1 (fr) | Medicament pour le traitement de la maladie de parkinson | |
| WO2011089576A3 (en) | Novel compositions for reducing abeta 42 production and their use in treating alzheimer's disease (ad) | |
| WO2009117283A3 (en) | Quinolizidinone m1 receptor positive allosteric modulators |